Literature DB >> 31567344

Diabetes Insipidus After Discontinuation of Vasopressin Infusion for Treatment of Shock.

Hannah Ferenchick1, Nail Cemalovic1, Nadia Ferguson2, Peter V Dicpinigaitis1.   

Abstract

OBJECTIVES: Vasopressin has achieved common usage for the treatment of catecholamine-requiring and catecholamine-resistant shock. Diabetes insipidus is a syndrome characterized by excretion of abnormally large volumes of dilute urine. To date, very few reports of diabetes insipidus after discontinuation of vasopressin infusion have been published; the majority of previous reports describe neurosurgical patients. The purpose of the present study was to investigate the occurrence rate of diabetes insipidus after discontinuation of vasopressin infusion among patients treated with vasopressin infusion for shock.
DESIGN: Retrospective analysis of electronic health records of patients receiving continuous vasopressin infusion for the treatment of shock within a 5-year period (2012-2016).
SETTING: Medical, surgical, and cardiothoracic ICUs within one academic medical center. PATIENTS: One-thousand eight-hundred ninety-six patients received vasopressin infusion for the treatment of shock.
INTERVENTIONS: None.
MEASUREMENTS AND MAIN RESULTS: The occurrence rate of diabetes insipidus after discontinuation of vasopressin infusion was 1.53% among all patients. Sixteen of 29 patients with diabetes insipidus after discontinuation of vasopressin infusion had undergone cardiothoracic intervention, such as coronary artery bypass graft and valve replacement surgery, extracorporeal membrane oxygenation, and placement of ventricular assist devices. No neurosurgical patients were identified in our cohort. In a control group of patients receiving norepinephrine but not vasopressin infusion for treatment of shock, criteria for diabetes insipidus were observed in two of 1,320 subjects (0.15%).
CONCLUSIONS: Despite a paucity of published reports, diabetes insipidus after discontinuation of vasopressin infusion appears not to be a rare phenomenon, and is likely to be encountered by intensivists who regularly employ vasopressin for the treatment of vasoplegic shock. Previous reports consisted predominantly of neurosurgical patients. Our findings demonstrate the occurrence of diabetes insipidus after discontinuation of vasopressin infusion among patients with septic shock as well as vasoplegic shock after cardiothoracic intervention. The mechanism of diabetes insipidus after discontinuation of vasopressin infusion remains to be elucidated but may involve transient downregulation of V2 receptors induced by exposure to supraphysiological doses of vasopressin.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31567344      PMCID: PMC7086483          DOI: 10.1097/CCM.0000000000004045

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  8 in total

Review 1.  Causes of reversible nephrogenic diabetes insipidus: a systematic review.

Authors:  Camelia G Garofeanu; Mathew Weir; M Patricia Rosas-Arellano; Garth Henson; Amit X Garg; William F Clark
Journal:  Am J Kidney Dis       Date:  2005-04       Impact factor: 8.860

2.  Effects of the discontinuation sequence of norepinephrine and vasopressin on hypotension incidence in patients with septic shock: A meta-analysis.

Authors:  Gary Duclos; Karine Baumstarck; Martin Dünser; Laurent Zieleskiewicz; Marc Leone
Journal:  Heart Lung       Date:  2019-05-22       Impact factor: 2.210

3.  Effects of Norepinephrine and Vasopressin Discontinuation Order in the Recovery Phase of Septic Shock: A Systematic Review and Individual Patient Data Meta-Analysis.

Authors:  Drayton A Hammond; Gretchen L Sacha; Brittany D Bissell; Nadine Musallam; Diana Altshuler; Alexander H Flannery; Simon W Lam; Seth R Bauer
Journal:  Pharmacotherapy       Date:  2019-04-15       Impact factor: 4.705

4.  Diabetes Insipidus After Discontinuation of Vasopressin Infusion for Treatment of Shock.

Authors:  Hannah Ferenchick; Nail Cemalovic; Nadia Ferguson; Peter V Dicpinigaitis
Journal:  Crit Care Med       Date:  2019-12       Impact factor: 7.598

5.  Leucyl/cystinyl aminopeptidase gene variants in septic shock.

Authors:  Taka-Aki Nakada; James A Russell; Hugh Wellman; John H Boyd; Emiri Nakada; Katherine R Thain; Simone A Thair; Hiroyuki Hirasawa; Shigeto Oda; Keith R Walley
Journal:  Chest       Date:  2011-02-17       Impact factor: 9.410

6.  Diabetes insipidus after discontinuation of vasopressin infusion for septic shock.

Authors:  H Rana; N Ferguson; P V Dicpinigaitis
Journal:  J Clin Pharm Ther       Date:  2017-09-11       Impact factor: 2.512

Review 7.  Diabetes insipidus.

Authors:  Mirjam Christ-Crain; Daniel G Bichet; Wiebke K Fenske; Morris B Goldman; Soren Rittig; Joseph G Verbalis; Alan S Verkman
Journal:  Nat Rev Dis Primers       Date:  2019-08-08       Impact factor: 52.329

8.  Discontinuation of Vasopressin Before Norepinephrine in the Recovery Phase of Septic Shock.

Authors:  Drayton A Hammond; Kelsey McCain; Jacob T Painter; Oktawia A Clem; Julia Cullen; Amy L Brotherton; Divyan Chopra; Nikhil Meena
Journal:  J Intensive Care Med       Date:  2017-06-15       Impact factor: 3.510

  8 in total
  3 in total

1.  Diabetes Insipidus After Discontinuation of Vasopressin Infusion for Treatment of Shock.

Authors:  Hannah Ferenchick; Nail Cemalovic; Nadia Ferguson; Peter V Dicpinigaitis
Journal:  Crit Care Med       Date:  2019-12       Impact factor: 7.598

2.  Sudden Vasopressin Withdrawal Causing Transient Central Diabetes Insipidus: A Case Report.

Authors:  Ramakanth Pata; Nway Nway; Ilana K Logvinsky; Innocent Lutaya; Tutul Chowdhury
Journal:  Cureus       Date:  2022-05-13

3.  Transient Central Diabetes Insipidus Occurring After Vasopressin Infusion.

Authors:  Elizabeth A Cristiano; Ashley Harris; Kristin Grdinovac
Journal:  AACE Clin Case Rep       Date:  2021-06-16
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.